Do BRAF inhibitors select for populations with different disease progression kinetics?

被引：24

作者：

Ascierto, Paolo Antonio ^{[1
]}

Simeone, Ester ^{[1
]}

Grimaldi, Antonio Maria ^{[1
]}

Curvietto, Marcello ^{[1
]}

Esposito, Assunta ^{[1
]}

Palmieri, Giuseppe ^{[2
]}

Mozzillo, Nicola ^{[3
]}

机构：

[1] Ist Nazl Tumori Fdn G Pascale, Dept Melanoma, Unit Melanoma Canc Immunotherapy & Innovat Therap, Naples, Italy

[2] CNR, Inst Biomol Chem, Unit Canc Genet, Sassari, Italy

[3] Ist Nazl Tumori Fdn G Pascale, Dept Melanoma, Unit Melanoma & Sarcoma Surg, Naples, Italy

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷

关键词：

IPILIMUMAB; MELANOMA;

D O I：

10.1186/1479-5876-11-61

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experience a very rapid progression of disease. Such selectivity for more rapid disease progression may mean these patients do not receive the same benefit from subsequent treatment with ipilimumab as patients without prior BRAF inhibitor treatment. The current challenge is focused on how to identify and approach the two populations of fast and slow progressors and recent hypothesis suggest that treatment choice could be guided by baseline risk factors. However, no data have yet defined which the best sequence is and more research is needed to identify predictors of response in patients with metastatic melanoma to help guide whether a BRAF inhibitor or ipilimumab should be used first in sequential therapy.

引用

页数：3

共 9 条

[1]

Ackerman A, 2012, J CLIN ONCOL, V30

[2]

Ascierto PA, 2012, ANN ONCOL, V23, P367

[3]

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Giannarelli, Diana ;

Grimaldi, Antonio M. ;

Romano, Anna ;

Mozzillo, Nicola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10

[4]

Melanoma: A model for testing new agents in combination therapies [J].

Ascierto, Paolo A. ;

Streicher, Howard Z. ;

Sznol, Mario .

JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8

[5]

Clinical Trial Result Information, BRIM 3 RAND OP LAB C

[6]

Clinical Trial Result Information, OP LAB MULT STUD EFF

[7]

Fisher R, 2012, PIGM CELL MELANOMA R, V25, P856

[8]

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[9]

Which drug, and when, for patients with BRAF-mutant melanoma? [J].

Jang, Sekwon ;

Atkins, Michael B. .

LANCET ONCOLOGY, 2013, 14 (02) :E60-E69

← 1 →